Beovu - direct healthcare professional communication (DHPC)

Brolucizumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Beovu ® (brolucizumab): Updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion

Key facts

• Medicine name:
  Beovu
• Active substance:
  Brolucizumab
• Therapeutic area (MeSH):
  Wet Macular Degeneration
• Procedure number:
  EMEA/H/C/004913
• Regulatory outcome:
  Variation
• DHPC type:
  Type II variation
• Human ATC codes:
  S01
• Dissemination date:
  05/11/2021